Tirzepatide
- Status:
- Red
- Decision Date:
- November 2022
Comments
RED: NICE TA924 - Tirzepatide
for treating type 2 diabetes. RED recommendation as holding position for TA compliance. ICB commissioned (Decision date November 2023)Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
search again